ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Gap Up to $13.22

ABIVAX Société Anonyme (NASDAQ:ABVXGet Free Report) gapped up prior to trading on Monday . The stock had previously closed at $13.22, but opened at $13.56. ABIVAX Société Anonyme shares last traded at $13.55, with a volume of 2,855 shares traded.

Analyst Ratings Changes

Several research analysts have commented on ABVX shares. BTIG Research started coverage on ABIVAX Société Anonyme in a research report on Monday, May 20th. They issued a “buy” rating and a $43.00 price target on the stock. Piper Sandler started coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an “overweight” rating and a $42.00 price target on the stock. Guggenheim initiated coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Morgan Stanley lifted their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.20.

Read Our Latest Stock Report on ABVX

ABIVAX Société Anonyme Trading Down 0.4 %

The company has a fifty day moving average price of $14.02 and a two-hundred day moving average price of $13.38. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.23.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after buying an additional 131,414 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after buying an additional 31,331 shares in the last quarter. Capstone Investment Advisors LLC boosted its stake in ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after buying an additional 5,199 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in ABIVAX Société Anonyme in the 1st quarter valued at $81,000. Finally, Rosalind Advisors Inc. bought a new stake in shares of ABIVAX Société Anonyme during the first quarter worth $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

(Get Free Report)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Featured Stories

Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.